Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
The current price of CLM.F is €4.17 EUR — it has increased by +5.3% in the past 24 hours. Watch Clearside Biomedical stock price performance more closely on the chart.
What is Clearside Biomedical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Clearside Biomedical stocks are traded under the ticker CLM.F.
Is Clearside Biomedical stock price growing?▼
CLM.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Clearside Biomedical has showed a -66.51% decrease.
What is Clearside Biomedical revenue for the last year?▼
Clearside Biomedical revenue for the last year amounts to 1.52M EUR.
What is Clearside Biomedical net income for the last year?▼
CLM.F net income for the last year is -31.95M EUR.
How many employees does Clearside Biomedical have?▼
As of April 01, 2026, the company has 32 employees.
In which sector is Clearside Biomedical located?▼
Clearside Biomedical operates in the Health Care sector.
When did Clearside Biomedical complete a stock split?▼
The last stock split for Clearside Biomedical was on September 15, 2025 with a ratio of 1:15.
Where is Clearside Biomedical headquartered?▼
Clearside Biomedical is headquartered in Alpharetta, US.